TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
SG monotherapy demonstrated a relatively high ORR with rapid responses; this was feasible with a manageable toxicity profile in cisplatin-ineligible patients who had progression after CPI therapy. Limitations include a moderate sample size and lack of random assignment. These results warrant further evaluation of SG alone and in combinations in patients with LA/mUC.
Authors
- Cora Nanette Sternberg (ORCID: https://orcid.org/0000-0003-3938-2627)
- Scott T. Tagawa (ORCID: https://orcid.org/0000-0003-2777-8587)
- Arash Rezazadeh Kalebasty
- Julia Tonelli (ORCID: https://orcid.org/0009-0006-7503-5189)
- Manojkumar Bupathi (ORCID: https://orcid.org/0009-0003-5613-3283)
- Luke T. Nordquist
- Rohit Jain (ORCID: https://orcid.org/0000-0002-4905-462X)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Daniel Peter Petrylak (ORCID: https://orcid.org/0000-0001-6165-5797)
- Morganna Vance
- Huafeng Zhou
- Chethan Ramamurthy (ORCID: https://orcid.org/0000-0003-3935-9638)
- Chandler Park (ORCID: https://orcid.org/0009-0006-5292-2981)
- Arjun Vasant Balar (ORCID: https://orcid.org/0000-0003-3949-5656)
- Julia Tonelli
- Saby George (ORCID: https://orcid.org/0000-0002-0444-5870)
- Phillip L. Palmbos (ORCID: https://orcid.org/0000-0002-3134-2965)
- Nancy B. Davis (ORCID: https://orcid.org/0000-0002-7933-2280)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
- Morganna Vance
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Vanderbilt University (US)
- University of Washington (US)
- Norton Healthcare (US)
- University of California, Irvine (US)
- Cornell University (US)
- Université Paris-Saclay (FR)
- University of Michigan (US)
- Huntsman Cancer Institute (US)
- Institut Gustave Roussy (FR)
- Moffitt Cancer Center (US)
- Yale University (US)
- NYU Langone Health (US)
- Fred Hutch Cancer Center (US)
- Reckitt Benckiser (United States) (US)
- Rocky Mountain Cancer Centers (US)
- Gilead Sciences (United States) (US)
- Vanderbilt-Ingram Cancer Center
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1200/jco.23.01720
- Citations
- 20
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.88
Funders
- Gilead Sciences